Chondroitin sulfate effect on induced arthritis in rats
| Autor: | Nicola Volpi, Danica Mihalova, Silvester Ponist, Viera Kuncirova, Katarína Bauerová, Ema Paulovičová |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Male
Chondroitin sulfate Neutrophils Chondroitin Sulfate Effect On Induced Arthritis In Rats medicine.medical_treatment Oral route Biomedical Engineering Arthritis Pharmacology medicine.disease_cause Antioxidants chemistry.chemical_compound Rheumatology Oral administration Osteoarthritis medicine Animals Orthopedics and Sports Medicine Intradermal injection Rheumatoid arthritis Glycosaminoglycans Phagocytes Adjuvant arthritis business.industry Chondroitin Sulfates gamma-Glutamyltransferase medicine.disease Arthritis Experimental Hindlimb Rats Disease Models Animal Oxidative Stress C-Reactive Protein chemistry Rats Inbred Lew Immunology Cytokines Polyarthritis business Adjuvant Oxidative stress |
| Zdroj: | Osteoarthritis and Cartilage. 19(11):1373-1379 |
| ISSN: | 1063-4584 |
| DOI: | 10.1016/j.joca.2011.08.006 |
| Popis: | Summary Objective Rodent models of osteoarthritis and rheumatoid arthritis are useful tools to study these disease processes. Adjuvant arthritis (AAR) is a model of polyarthritis widely used for preclinical testing of antiarthritis substances. We report the effect of two different doses of highly purified chondroitin sulfate (CS) pharmaceutical grade in the AAR animal model after oral administration. Design AAR was induced by a single intradermal injection of heat-inactivated Mycobacterium butyricum in incomplete Freund's adjuvant. The experiments included healthy animals, untreated arthritic animals, arthritic animals having been administered 300 or 900 mg/kg of CS daily, 14 days before AAR induction until the end of the experiment (day 28), arthritic animals having been administered 300 or 900 mg/kg of CS daily, from day 1 until the end of the experiment. Results CS was capable of significantly reducing the severity of arthritis along with oxidative stress, a consequence of chronic inflammatory processes occurring in AAR. The CS pre-treatment regimen was effective throughout the whole subacute phase, while treatment from day 1 proved effective only in the chronic period. The effects were confirmed by improved total antioxidant status and γ-glutamyltransferase activity. CS administered under a pre-treatment regimen was also able to reduce the production of pro-inflammatory cytokines, C-reactive protein in plasma, phagocytic activity and the intracellular oxidative burst of neutrophils. Conclusions CS proved to be effective in slowing down AAR development and in reducing disease markers, thus supporting its beneficial activity as a drug in humans. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect